Remdesivir is an approved antiviral treatment for COVID-19, but it needs to be administered intravenously. Here, Cox et al. show that GS-621763, a prodrug of remdesivir parent nucleoside GS-441524 has good oral bioavailability and inhibits SARS-CoV-2 and variants of concerns in ferrets
Abstract The ongoing SARS‐CoV‐2 pandemic stresses the need for effective antiviral drugs that can qu...
BACKGROUND: The novel human coronavirus SARS-CoV-2 is a major ongoing global threat with huge econom...
GS-441524, an RNA‐dependent RNA polymerase (RdRp) inhibitor, is a 1′-CN-substituted adenine C-nucleo...
The SARS-CoV-2 pandemic continues to spread worldwide, with rapidly increasing numbers of mortalitie...
The coronavirus disease 2019 (COVID-19) pandemic remains uncontrolled despite the rapid rollout of s...
The coronavirus disease 2019 (COVID-19) pandemic remains uncontrolled despite the rapid rollout of s...
There has been an increasing interest in remdesivir research within the scientific medical community...
Remdesivir was the first antiviral drug to be approved for the treatment of severe COVID-19; followe...
Remdesivir was the first antiviral drug to be approved for the treatment of severe COVID-19; followe...
Remdesivir (RDV) is the only US Food and Drug Administration (FDA)-approved drug for treating COVID-...
Patients and physicians worldwide are facing tremendous health care hazards that are caused by the o...
Recent international epidemics of coronavirus-associated illnesses underscore the urgent medical and...
Innumerable future deaths and hospitalizations could be avoided through improved pandemic preparedne...
COVID-19 patients with severe symptoms still lack antiviral treatment options. Although remdesivir i...
COVID-19 patients with severe symptoms still lack antiviral treatment options. Although remdesivir i...
Abstract The ongoing SARS‐CoV‐2 pandemic stresses the need for effective antiviral drugs that can qu...
BACKGROUND: The novel human coronavirus SARS-CoV-2 is a major ongoing global threat with huge econom...
GS-441524, an RNA‐dependent RNA polymerase (RdRp) inhibitor, is a 1′-CN-substituted adenine C-nucleo...
The SARS-CoV-2 pandemic continues to spread worldwide, with rapidly increasing numbers of mortalitie...
The coronavirus disease 2019 (COVID-19) pandemic remains uncontrolled despite the rapid rollout of s...
The coronavirus disease 2019 (COVID-19) pandemic remains uncontrolled despite the rapid rollout of s...
There has been an increasing interest in remdesivir research within the scientific medical community...
Remdesivir was the first antiviral drug to be approved for the treatment of severe COVID-19; followe...
Remdesivir was the first antiviral drug to be approved for the treatment of severe COVID-19; followe...
Remdesivir (RDV) is the only US Food and Drug Administration (FDA)-approved drug for treating COVID-...
Patients and physicians worldwide are facing tremendous health care hazards that are caused by the o...
Recent international epidemics of coronavirus-associated illnesses underscore the urgent medical and...
Innumerable future deaths and hospitalizations could be avoided through improved pandemic preparedne...
COVID-19 patients with severe symptoms still lack antiviral treatment options. Although remdesivir i...
COVID-19 patients with severe symptoms still lack antiviral treatment options. Although remdesivir i...
Abstract The ongoing SARS‐CoV‐2 pandemic stresses the need for effective antiviral drugs that can qu...
BACKGROUND: The novel human coronavirus SARS-CoV-2 is a major ongoing global threat with huge econom...
GS-441524, an RNA‐dependent RNA polymerase (RdRp) inhibitor, is a 1′-CN-substituted adenine C-nucleo...